Investor Flagship VentureLabs IV, LLC
13D/G Filings

This page shows a list of all the recent 13D/G filings made by Flagship VentureLabs IV, LLC . Schedule 13D is commonly referred to as a “beneficial ownership report.” The term "beneficial owner" is defined under SEC rules. It includes any person who directly or indirectly shares voting power or investment power (the power to sell the security).

When a person or group of persons acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities, they are required to file a Schedule 13D within ten days after the purchase. Click the link icon to see the full transaction history.

Date Form Target Prev
Shares
Current
Shares
Change
(Percent)
Ownership
(Percent)
Change
(Percent)
2023-02-14 13G/A RUBY / Rubius Therapeutics, Inc. 38,606,526
2022-10-17 13D/A AXLA / Axcella Health Inc. 18,867,785 29,251,545
2022-09-23 13D/A AXLA / Axcella Health Inc. 18,867,785 18,867,785
2022-07-07 13D/A MCRB / Seres Therapeutics, Inc. 15,049,991 23,493,063
2022-03-18 13D/A AXLA / Axcella Health Inc. 12,548,414 18,867,785
2020-11-25 13D/A MCRB / Seres Therapeutics, Inc. 21,646,905 15,049,991
2020-05-20 13D AXLA / Axcella Health Inc. 8,748,414 12,548,414
2019-06-28 13D MCRB / Seres Therapeutics, Inc. 21,646,905
2019-05-23 13D AXLA / Axcella Health Inc. 8,748,414